In our laboratory we study how the deregulation of certain proteins occurs in the evolution of breast cancer. Resistance to conventional treatments in breast cancer occurs at a high frequency, evolving in our country to approximately 14,000 per year. In our laboratory we study how the deregulation of certain proteins occurs in the evolution of breast cancer. Resistance to conventional treatments in breast cancer occurs at a high frequency, evolving in our country to approximately 14,000 per year.

There are few clinical approaches in cancer where the therapeutic strategy is decided based on the expression of a particular target pathway. Such is the case of the presence of alterations in the PI3K alpha catalytic subunit gene, PIK3CA, called mutant PIK3CA, both in tumor tissue and in free circular DNA, to indicate the use of a specific inhibitor of PI3Kalpha, Alpelisib in advanced breast cancer. But in addition to the high costs for the determination of mutant PIK3CA, it must be considered that the determination of alterations in a single gene cannot be entirely informative. Therefore, using preclinical experimental models and samples from breast cancer patients, we propose using other more accessible detection methods and extending this determination to other factors of the PI3K pathway, also adding particular components of other related pathways such as CDK4/6. These pathways are involved in mechanisms of resistance and tumor escape, such as regulators of the cell cycle and other processes of cell invasion and survival, among others.

In this way we hope to contribute to expanding and facilitating the availability of biomarkers that can be used in the clinic to better stratify breast tumors and direct the therapeutic strategy more specifically and selectively.